Tirzepatide (Mounjaro) Regulatory Status in the UK and Ireland

Questions about tirzepatide's legal status in the United Kingdom and Ireland have become more frequent as the drug's profile has grown — and as reports of counterfeit or unlicensed versions have accumulated. The regulatory picture is clearer than the online conversation often suggests. Tirzepatide has held a formal marketing authorisation in both jurisdictions for several years. The problem is not that the drug lacks approval; it is that a substantial volume of products falsely claiming to be tirzepatide — or tirzepatide pens sourced outside the authorised supply chain — have reached consumers through unregulated channels.

This article records the authorisation history in each jurisdiction, defines what prescription-only status means in practice, identifies the sole authorised product, and describes the enforcement actions taken against unlicensed alternatives.

MHRA Authorisation in the United Kingdom

The Medicines and Healthcare products Regulatory Agency (MHRA) is the competent authority for medicines in Great Britain (England, Scotland, and Wales). Since Brexit, it operates independently from the European Medicines Agency (EMA), though it draws on common international evidence standards under ICH guidelines.

Type 2 Diabetes — September 2022

Tirzepatide received its first MHRA marketing authorisation in September 2022 under the brand name Mounjaro, for the treatment of type 2 diabetes mellitus in adults. The authorisation was granted to Eli Lilly Nederland B.V. as Marketing Authorisation Holder (MAH). The clinical basis for this authorisation was the SURPASS clinical programme, a series of phase 3 trials published in peer-reviewed journals including The New England Journal of Medicine and The Lancet, demonstrating glycaemic reduction in adults with type 2 diabetes. MHRA's product-level documentation for this authorisation is publicly accessible through its Product Information database.

Weight Management — November 2023

In November 2023, the MHRA granted a second authorisation for Mounjaro — extending the indication to include chronic weight management in adults with an initial body mass index (BMI) meeting specific criteria, in conjunction with a reduced-calorie diet and increased physical activity. The clinical basis for this extension was the SURMOUNT trial programme, with key efficacy and safety data published in the New England Journal of Medicine in 2022 (SURMOUNT-1, Jastreboff et al., NEJM 387:205–216).

These two authorisations together define the full scope of tirzepatide's lawful status in Great Britain: a prescription-only injectable medicine with two authorised indications, both covered by the Mounjaro brand.

Authorisation in Ireland via the EMA and HPRA

Ireland is a member state of the European Union and implements the EU centrally-authorised medicines framework. Under this system, the European Medicines Agency (EMA) conducts the scientific evaluation and grants a centralised marketing authorisation valid across all EU member states. The Health Products Regulatory Authority (HPRA) is Ireland's national competent authority; it applies and enforces the centrally-granted authorisation domestically.

The EMA granted a centralised marketing authorisation for Mounjaro (tirzepatide) for type 2 diabetes in September 2022, the same month as the MHRA's UK authorisation. The weight management indication followed in November 2023, again in alignment with the MHRA timeline. Mounjaro's EU summary of product characteristics (SmPC) and the European Public Assessment Report (EPAR) are publicly available through the EMA's medicines database at ema.europa.eu.

For Ireland specifically, the HPRA maintains a searchable medicines register at hpra.ie where Mounjaro's authorisation status can be verified directly. The HPRA has also issued public communications warning against the purchase of tirzepatide products from unregulated internet sources.

What 'Prescription-Only' Means in Each Jurisdiction

Both the UK and Ireland classify Mounjaro as a prescription-only medicine (POM). This classification is not administrative shorthand — it has specific legal consequences in each jurisdiction that are worth understanding clearly.

In the United Kingdom

Under the Human Medicines Regulations 2012 (SI 2012/1916), a prescription-only medicine may only be supplied against a valid written prescription issued by a practitioner authorised to prescribe in the UK. This includes registered medical practitioners (doctors), certain nurse prescribers, pharmacist prescribers, and other suitably qualified prescribers on the relevant NHS or private registers. A prescription must name the patient, the medicine, the quantity, and the prescriber's details. A pharmacist is not permitted to dispense a POM without such a prescription.

Supplying a POM without a prescription — including selling it, offering it for sale online, or importing it for onward supply — is an offence under the Human Medicines Regulations. The MHRA enforces these provisions and coordinates with law enforcement where criminal conduct is involved. Possession by a patient for personal use under a valid prescription is lawful; possession without a prescription may give rise to questions about the supply chain rather than the patient directly, but obtaining a POM through an illegal channel remains a matter the authorities take seriously.

In Ireland

In Ireland, prescription-only status is governed by the Medicinal Products (Prescription and Control of Supply) Regulations 2003 (SI 540/2003) as amended. A POM may only be dispensed by a registered pharmacist against a prescription from an authorised prescriber — a registered medical practitioner, dentist, or nurse/midwife prescriber as appropriate. Supplying, importing, or advertising a POM outside this framework constitutes a breach of Irish medicines law, enforceable by the HPRA. The HPRA has issued public notices specifically addressing unlicensed tirzepatide products and the risks associated with products purchased outside the regulated pharmacy supply chain.

The Authorised Product: Mounjaro Pens by Eli Lilly

In both jurisdictions, the sole authorised tirzepatide product is Mounjaro, manufactured and distributed by Eli Lilly. It is presented as a pre-filled, single-use auto-injector pen. Authorised pens bear the Mounjaro brand name prominently on the outer carton, display the strength clearly, include the Marketing Authorisation number (for the UK, an MHRA MA number; for the EU, an EMA central MA number), and carry the name and address of the Marketing Authorisation Holder (Eli Lilly Nederland B.V.) and the manufacturer's release site.

Each pen and its carton must carry the relevant product information leaflet in the language of the jurisdiction. In the UK, the patient information leaflet (PIL) corresponds to the MHRA-approved text. In Ireland, the EMA-approved SmPC and PIL apply. Patient-facing information is available through the MHRA's Yellow Card scheme website for UK patients, and through the HPRA's website for Irish patients.

The authorised product is available exclusively through licensed pharmacy channels against a valid prescription. It is not available for direct purchase without a prescription from any legitimate UK or Irish source.

What Is Not Authorised: The Wave of Counterfeit and Unlicensed Pens

The commercial success of Mounjaro created an incentive for unlicensed alternatives. From 2025 onwards, the MHRA began documenting a pattern of counterfeit and unlicensed tirzepatide products entering the UK through online channels, grey imports, and some physical outlets operating outside the regulated supply chain. The volume and frequency of enforcement actions accelerated through 2025 and into 2026.

MHRA Enforcement Actions

The MHRA classifies seized products in two distinct categories: counterfeit medicines are those that falsely present themselves as a genuine authorised product — in this case, bearing Mounjaro branding and mimicking the pen design of the authorised product while not originating from Eli Lilly's authorised manufacturing and supply chain. Unlicensed products are those that may contain tirzepatide (or claim to) but have not been granted a UK marketing authorisation, often imported from jurisdictions with different or no applicable regulatory frameworks.

Both categories represent a serious public health concern independent of efficacy questions. Counterfeit products seized by the MHRA have in documented cases contained incorrect active ingredient concentrations, contained no active ingredient at all, or contained undisclosed substances. The sterility and endotoxin status of such products — critical considerations for any injectable — cannot be assumed, given that they originate outside the validated manufacturing and quality control systems required of authorised medicines.

Why Counterfeit Injectables Are a Distinct Risk

For an oral medicine, a counterfeit or substandard product may result in reduced efficacy or unexpected side effects. For an injectable, the risk profile is categorically different. An injectable product that has not been manufactured under GMP conditions, tested for sterility, and verified for endotoxin content can introduce pathogens or pyrogens directly into tissue. The physical presentation of a pen — its colour, label, and packaging — does not verify its contents. Only analytical testing of the actual material in the vial can do that.

This is the point at which verification reasoning applies to the medicines domain as clearly as it applies to research peptides: the label is a claim, not evidence. Evidence is the analytical record that connects the contents of a specific unit to a quality-assured manufacturing process.

Jurisdiction Summary

Jurisdiction	Regulator	Authorised product	T2D authorisation	Weight management	Classification
United Kingdom	MHRA	Mounjaro (Eli Lilly)	September 2022	November 2023	Prescription-only (POM)
Ireland	EMA / HPRA	Mounjaro (Eli Lilly)	September 2022	November 2023	Prescription-only (POM)

A Note on Northern Ireland

Northern Ireland occupies a distinct regulatory position. Under the Windsor Framework, Northern Ireland continues to apply EU medicines law for human medicines, meaning that the EMA centralised authorisation framework applies there — as it does in Ireland — rather than the MHRA Great Britain framework. For tirzepatide, the practical effect is that the same EU marketing authorisation that covers Ireland also covers Northern Ireland, with the MHRA playing a role in enforcement coordination. Patients and healthcare providers in Northern Ireland should confirm current applicable provisions with the relevant health authority, as the exact arrangements have evolved with ongoing Windsor Framework implementation.

How to Verify Authorised Status

Both regulators maintain public-facing registers where authorisation status can be confirmed. These are primary sources — they reflect the current state of the authorisation, including any updates, suspensions, or variations.

• MHRA (UK): The MHRA's Products database, searchable at products.mhra.gov.uk, lists all UK-authorised human medicines with their MA numbers, indications, and authorisation holders. Mounjaro appears there with its full product information.
• EMA (EU including Ireland): The EMA's medicines database at ema.europa.eu/en/medicines provides the European Public Assessment Report (EPAR) for Mounjaro, including the full history of the centralised authorisation and all approved indications.
• HPRA (Ireland): The HPRA's medicines register at hpra.ie allows confirmation of Irish-market authorisation status and has issued specific safety communications regarding unlicensed tirzepatide.

A product that does not appear in these registers, or appears with a different brand name, a different Marketing Authorisation Holder, or a different regulatory number from what is on its packaging, is not verified as authorised. That is the verification principle applied to the medicines context.